Prognostic values of proliferative markers ki-67 and repp86 in breast cancer

Archives of Iranian Medicine

Volumn 10, Issue 1, 2007, Pages 27-31

  Mohsenifar, Jaleh ^a   Almassi Aghdam, Maryam ^a   Mohammad Taheri, Zohreh ^b   Zare, Khandan ^c   Jafari, Bahar ^a   Atri, Morteza ^c   Mortazavi, Seyed Hossein ^d   Azadeh, Payam ^c   Bagherzadeh, Mostafa ^e   Azargashb, Eznollah ^f   Rahimi, Farzaneh ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e Noor Pathobiology Lab   (Iran)

^f SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Breast cancer; Immunohistochemistry; Ki 67; Repp86; Tumor marker

Indexed keywords

KI 67 ANTIGEN; MONOCLONAL ANTIBODY; NUCLEAR PROTEIN; PROTEIN REPP86; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER MORTALITY; CANCER RECURRENCE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL LABELING; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ACTIVITY; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MOLECULAR BIOLOGY; PATIENT CARE; PROGNOSIS; TUMOR CELL;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM STAGING; NUCLEAR PROTEINS; ODDS RATIO; PROGNOSIS; RETROSPECTIVE STUDIES; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 33846702494     PISSN: 10292977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Rosai J, Ackerman LV. Rosai and Ackerman's Surgical Pathology. 9th ed. Edinburgh: New York: Mosby; 2004.
2. Kumar V, Abbas AK, Fausto N, Robbins SL. Robbins and Cotran, Pathologic Basis of Disease. 7th ed: Philadelphia: Elsevier Saunders; c2005.
3. Heidebrecht HJ, Adam-Klages S, Szczepanowski M, Pollmann M, Buck F, Endl E, et al. Repp86: a human protein associated in the progression of mitosis. Mol Cancer Res. 2003; 1: 271-279.
4. van Diest PJ, van der Wall E, Baak JP. Propostic value of proliferation in invasive breast cancer: a review. J Clin Pathol. 2004; 57: 675-681.
5. Krams M, Heidebrecht HJ, Hero B, Berthold F, Harms D, Parwaresch R, et al. Repp86 expression and outcome in patients with neuroblastoma. J Clin Oncol. 2003; 21: 1810-1818.
6. Crosier M, Scott D, Wilson RG, Griffiths CD, May FE, Westley BR. Differences in ki-67 and c-erbB2 expression between screen-detected and true interval breast cancers. Clin Cancer Res. 1999/; 5: 2682-2688.
7. Breast Cancer at Baylor College of Medicine. Prognostic biomarkers - ki-67 proliferation index [cited 2005]. Available from: URL: http://www.breastcenter.tmc.edu/research/cores/path/services/ki67.htm.
8. Kuhling H, Alm P, Olsson H, Ferno M, Baldetorp B, Parwaresch R, et al. Expression of cyclins E, A, and B, and prognosis in lymph node-negative breast cancer. J Pathol, 2003; 199: 424-431.
9. Weikel W, Beck T, Rosenthal H, Herzog R. The immunohistochemical growth fraction (ki-67) of breast cancers: relations to tumor spread, tumor morphology and receptor testing. Geburtshilfe Frauenheilkd. 1989; 49: 277-282.
10. Rudolph P, Alm P, Heidebrecht HJ, Bolte H, Ratjen V, Baldetorp B, et al. Immunologic proliferation marker Ki-S2 as prognostic indicator for lymph node-negative breast cancer. J Natl Cancer Inst. 1999; 91: 271-278.
11. Rudolph P, Schubert C, Tamm S, Heidorn K, Hauschild A, Michalska I, et al. Telomerase activity in melanocytic lesions: a potential marker of tumor biology. Am J Pathol. 2000; 156: 1425-1432.
12. Bonatz G, Frahm SO, Klapper W, Helfenstein A, Heidorn K, Jonat W, et al. High telomerase activity is associated with cell cycle deregulation and rapid progression in endometrioid adenocarcinoma of the uterus. Hum Pathol. 2001; 32: 605-614.